Navidea Biopharmaceuticals Inc
F:NO1A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NO1A's latest stock split occurred on Apr 26, 2019
The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.
Before the split, NO1A traded at 0.0988 per share. Afterward, the share price was about 2.3085.
The adjusted shares began trading on Apr 26, 2019. This was the only stock split in NO1A's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 22, 2026
|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
1-for-100
/100
|
0.002 0.2 AUD | 0.17 0.17 AUD |
|
Apr 22, 2026
|
|
Architects Studio Japan Inc
TSE:6085
|
10-for-1
x10
|
3800 380 JPY | 430 430 JPY |
|
Apr 22, 2026
|
|
Freewon China Co Ltd
SSE:688678
|
1-for-1
x1
|
30.5 21.6857 CNY | 23.64 23.64 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
|
Apr 21, 2026
|
|
Canon Electronics Inc
OTC:CAOEF
|
1-for-6235122
/6235122
|
16.96 16.96 USD | N/A |
CHM
6085
688678
CAOEF
Navidea Biopharmaceuticals Inc
Glance View
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. The company is headquartered in Dublin Ohio, Ohio and currently employs 11 full-time employees. The firm is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. The company has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).
